Shilpa Medicare Ltd - Company Profile
Powered by 
All the data and insights you need on Shilpa Medicare Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Shilpa Medicare Ltd Strategy Report
- Understand Shilpa Medicare Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture, and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs) and formulations for both domestic and international markets. The company product portfolio is spread across non-oncology and oncology therapeutic areas. The formulations are provided in a full range of injectable and oral dosage forms. The company also offers contract research and manufacturing services for APIs, formulations, new drug delivery systems (NDDS), specialty chemicals, and biotech products. It exports its drug products to the US, Europe, and other international markets. The company has three R&D units, two formulations plants, two API plants in India. Shilpa Medicare is headquartered in Raichur, Karnataka, India.
Headquarters
India
Address
Shilpa House, #12-6-214/A1, Hyderabad Road, Raichur, Karnataka, 584135
Website
www.vbshilpa.com
Telephone
91 8532 238704
No of Employees
1,033
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SHILPAMED (NSE)
Revenue (2022)
$133.8M
-8.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-153.5%
(2022 vs 2021)
Market Cap*
$623.1M
Net Profit Margin (2022)
XYZ
-158.3%
(2022 vs 2021)
* As of and is in US$
Shilpa Medicare Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Active Pharmaceutical Ingredients | Continuous Flow Chemistry | VOMISTRIP |
| Formulations: | Formulation Development & Manufacturing | VOMISTRIP-4 |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company announced the acquisition of Pilnova Pharma Inc. |
| 2023 | Regulatory Approval | In May, the company secured approval US FDA for New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml. |
| 2022 | Regulatory Approval | In September, the company received approval from the CDSCO (Drug Controller General of India) for its Tranexamic Acid Spray. |
Competitor Comparison
| Key Parameters | Shilpa Medicare Ltd | Lupin Ltd | Glenmark Pharmaceuticals Ltd | GlaxoSmithKline Pharmaceuticals Ltd | J B Chemicals and Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Raichur | Mumbai | Mumbai | Mumbai | Mumbai |
| State/Province | Karnataka | Maharashtra | Maharashtra | Maharashtra | Maharashtra |
| No. of Employees | 1,033 | 18,971 | 15,556 | 3,680 | 5,095 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Omprakash Inani | Chairman | Executive Board | - | - |
| Alpesh Dalal | Chief Financial Officer | Senior Management | 2021 | 48 |
| Vishnukant Chaturbhuj Bhutada | Director; Managing Director | Executive Board | - | - |
| Sharath Reddy Kalakota | Vice President- Projects & Operations; Director | Executive Board | 2022 | - |
| Ganeshchandra Sonavane | President - Global R & D | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer